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Abstract
Background: The role of remission status in limited disease (LD) small-cell lung cancer (SCLC) patients treated with
definitive chemoradiotherapy (CRT) remains to be finally clarified.
Methods: Individual data from 184 patients treated with definitive CRT concurrently or sequentially were
retrospectively reviewed. Kaplan-Meier analysis as well as univariate and multivariate Cox regression models were
used to describe survival within patient subgroups defined by remission status.
Results: 71 (39 %) patients were treated in the concurrent, 113 (61 %) in the sequential CRT mode. Prophylactic
cranial irradiation (PCI) was applied in 71 (39 %) patients. 37 (20 %) patients developed local, while 89 (48 %)
distant recurrence. 58 (32 %) patients developed metachronous brain metastases. Complete, partial remission
and non-response (defined as stable and progressive disease) were documented in 65 (35 %), 77 (42 %), and 37
(20 %) patients, respectively. In complete responders median overall survival was 21.8 months (95CI: 18.6 – 25)
versus 14.9 (95 % CI: 11.7 – 18.2) (p = 0.041, log-rank test) and 11.5 months (95 % CI: 8.9 – 15.0) (p < 0.001, log-rank test)
in partial and non-responders, respectively. The same effect was documented for the time to progression and distant
metastasis-free survival. In the multivariate analysis achievement of complete remission as a variable shows a trend for
the prolonged time to progression (p = 0.1, HR 1.48) and distant metastasis-free survival (p = 0.06, HR 1.63) compared to
partial responders and was highly significant compared to non-responders.
Conclusion: In this treated heterogeneous LD SCLC patient cohort complete remission was associated with longer
time to progression, distant metastasis-free and overall survival compared to the non- and especially partial responders.
Keywords: Remission, Chemoradiotherapy, Limited disease, Small-cell, Lung cancer
Background
SCLC accounts for about 13 % of all lung cancer cases
with one third of the patients presenting with LD [1].
Due to the early tendency to systemic dissemination, LD
SCLC has a relatively rapid course with a median survival
for treated patients of approximately one and half a years
[1]. Multimodality treatment consisting of chemotherapy
and thoracic radiation therapy (TRT) represents a key
treatment stone. Additionally, PCI has shown to improve
overall survival due to prevention of brain metastasis
(BM) [2, 3]. Consecutive meta-analyses for LD SCLC
reported better long-term outcome when platinum-based
chemotherapy and early concurrent TRT are applied
[4, 5]. De Ruysscher et al. found that a short time
interval between the first day of any treatment and the
last day of TRT is associated with improved overall
survival (OS) [6]. Another retrospective study demon-
strated that duration of CRT, itself, correlates with OS in
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LD SCLC patients with poor initial performance status
(PS) successfully treated with multimodality therapy [7].
In 2013 Sun et al. published a phase III study investi-
gating the timing of TRT in the course of chemotherapy
in LD SCLC [8]. No differences were found in the remis-
sion rate and survival between early and late irradiation
groups. However, complete response was significantly
associated with better OS. A 1997 published trial on the
timing of TRT has already described significantly higher
complete remission rates associated with better long-
term outcome in the early versus late irradiation group
[9]. Correlation between remission status after CRT and
brain-metastasis free survival in LD SCLC has also been
previously documented [10].
The aim of the present study was firstly to establish a
correlation between response to multimodality treatment
and survival in a heterogeneous LD SCLC patient cohort
and secondly to compare different survival parameters




One hundred eighty-four patients from two institutions
with initial PS score of WHO 0–3 were diagnosed with
LD (UICC Stage I-III) SCLC and successfully treated
with definitive CRT in concurrent or sequential modes
from 1998 to 2011. Diagnosis was histologically proven
in all patients. LD was defined as disease confined to
one hemithorax with or without contralateral mediastinal
and ipsilateral supraclavicular lymph node involvement,
according to Murray et al. [11]. Evidence of pleural effu-
sion and involvement of the contralateral supraclavicular
and/or hilar lymph nodes was considered as an exclusion
criterion [12]. In all patients initial staging included bron-
choscopy with biopsy, CT scans of the chest and abdomen,
bone scintigraphy and contrast-enhanced cranial MRI. All
patients provided written informed consent before they
started treatment. Retrospective study was approved by
the University of Munich Ethic Committee.
Chemoradiotherapy
Concurrent CRT mode was conducted in 71 (39 %) pa-
tients and consisted of TRT starting with the first or
second cycle of chemotherapy followed by two to four
consolidation cycles. The sequential mode of treatment
was applied in 113 (61 %) patients consisting of four to
six chemotherapy cycles followed by TRT. The most
common chemotherapy regimen was a combination of
cisplatin either with etoposide or irinotecan. Chemo-
therapy was given in a 28-day cycle in patients treated
with concurrent CRT and in a 21-day cycle in patients
treated with sequential CRT according to Takada et al.
[13]. TRT was delivered on the linac with megavoltage
equipment (8–15 MV) using a coplanar multiple field
technique. Three-dimensional CT-simulated treatment
planning was performed. Planning target volume was
defined as a primary tumour bulk including involved
lymph nodes visualised on the pre-therapeutic CT with
1.0 cm margin. 96 % patients were treated 5 days a
week with daily fractions of 1.8/2.0 Gy to a total dose
of at least 54 Gy (range: 54 – 66Gy). 4 % of patients
were treated with hyperfractionated accelerated TRT
according to Turrisi AT et al. [14]. After completion of
CRT 71 patients (39 %) with good partial and complete
remission were treated with PCI (daily 2 Gy to a total
dose of 30–36 Gy).
Response assessment
Response evaluation was done within two weeks after
completion of CRT and based on CT scanning of thorax
and abdomen as well as bone scintigraphy. Contrast-
enhanced cranial MRI was routinely performed before
commencing PCI to exclude BM (Brain metastasis).
Follow-up care was performed every 3 months during the
first two years and every 6 months from the third year on-
wards. Response evaluation was based on the CT scans
and performed by radiologist. Tumor response was de-
fined according to Response Evaluation Criteria in Solid
Tumors criteria [15]. Complete remission was defined in
cases where staging did not demonstrate any signs of
tumor and bronchoscopy revealed a tumor-free biopsy.
Statistics
All patients were recorded until death. There is no median
follow-up due to the fact that the majority of patients died;
therefore follow-up was as complete as possible. Survival
rates were analysed according to Kaplan-Meier method
and were measured from the date of initial diagnosis
using SPSS 16.0 software. Kaplan-Meier analyses (pair-wise
comparisons) were used to compare survival curves for the
complete remission, partial remission and non-response
(stable and progressive disease) subgroups. Remission sta-
tus was also analysed for its association with time to pro-
gression (TTP), distant metastasis-free survival (DMFS)
and overall survival (OS) by univariate and multivariate
Cox regression models after adjustment for other prognos-
tic factors (borderline significant factors in the univariate
analysis).
Results
Patient and treatment characteristics
Patient characteristics are described in Table 1. Of 184
patients treated, 111 (60 %) were men and 73 (40 %)
were women. Median age at diagnosis was 63 years
(range: 34–83). 34 (19 %) patients were older than 70 years.
Median PS according to WHO for the entire cohort
was 1 (range: 0 to 3). 71 (39 %) patients were treated
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with concurrent and 113 (61 %) sequential treatment
modes. T3/4-Stage disease was diagnosed in 101 (55 %)
patients. 110 (60 %) patients presented with N-Stage 2
or 3. T1-T2 (<5 cm) primary tumors without lymph
node involvement were only detected in five (3 %) pa-
tients. Sufficient data on T- and N-stage were missing
in 26 (14 %) and 35 (19 %) cases, respectively. There
were no significant differences in regard to age, sex, PS
and TNM-stage between patients treated in the concur-
rent and sequential groups. Platinum-based chemotherapy
was applied in 164 (89 %) patients. 36 (20 %) patients were
treated with less than four cycles of chemotherapy. PCI
was applied in 71 (39 %) patients with good partial or
complete remission. Median duration of multimodality
treatment was 165 (range: 16–327) days. Median duration
of TRT was 43 (range: 16–76) and of chemotherapy 108
(range: 5–233) days, respectively.
Treatment response
Treatment response to definitive CRT is described in
Table 2. Objective response was found in 142 (77 %) pa-
tients. Complete remission was documented in 65 (35 %)
patients and was confirmed with bronchoscopy. 77 (42 %)
patients had a partial remission. 37 (20 %) patients had
non-response (stable or progressive disease). A lack of
data on remission status was documented in 5 (3 %) cases.
Local recurrence was found in 37 (20 %) patients. 89
(48 %) patients developed distant metastases. Metachro-
nous BMs were detected in 58 (32 %) patients. Median
OS, DMFS and TTP for the entire cohort were 16.8 (95
CI: 14.8 – 18.9), 18.2 (95 CI: 14.1 – 22.2) and 14.5 months
(95 CI: 11.9 – 17.1), respectively. No difference in survival
parameters could be found in patients treated with the
concurrent versus sequential modes.
Remission status and survival
Pair-wise comparisons for OS, DMFS and TTP within
the patient subgroups defined by remission status were
performed. Median OS in complete responders was 21.8
(95 % CI: 18.6 – 25) versus 14.9 (95 % CI: 11.7 – 18.2)
(p = 0.041, log-rank test) and 11.5 months (95 % CI:
8.9 – 15) (p < 0.001, log-rank test) in partial and non-
responders, respectively (Fig. 1). Considering the control
of systemic disease, median DMFS in patients with
complete remission was not reached (Fig. 2: see Plateau
was over 50 %) whereas in partial and non-responders,
it was only 16.6 (95 % CI: 11.9 – 21.2) (p = 0.009, log-rank
test) and 11.9 (95 % CI: 8.9 – 15) (p = 0.001, log-rank test)
months, respectively. The same effect was also shown for
the TTP: in complete responders it was 23.6 versus 13.5
(range: 9.2 – 17.7) (p = 0.027, log-rank test) and 10 (range:
6.1 – 13.9) (p < 0.0001, log-rank test) months in patients
with partial remission and stable/progressive disease,
respectively (Fig. 3: see Plateau).
In the multivariate analysis, comparing survival in
complete and partial responders, the trend for prolonged
TTP (p = 0.1, HR 1.48) and DMFS (p = 0.06, HR 1.63)
was demonstrated (Table 3). Significantly longer OS,
DMFS and TTP in complete responders compared to
non-responders were confirmed.
Discussion
The aim of this retrospective analysis was to establish
the role of remission status in LD SCLC patients treated
with chemotherapy and TRT without surgery and to
compare survival parameters in the different subgroups
defined by remission status. This study demonstrates a
clear correlation between achieved remission after primary
multimodality treatment and systemic disease control as
well as overall survival. Especially our results show that
complete response following CRT was associated with
Table 1 Patient- and treatment characteristics
Characteristics Number of Patients (N = 184) %
Age at diagnosis
Median 63 (range 34–83)








Platinum based 164 89
Non platinum based 20 11
Chemotherapy Cycles









Table 2 Distribution of treatment response to definitive
chemoradiotherapy
Treatment Response Number of Patients
(N = 184)
%
Complete remission 65 35
Partial remission 77 42
Non-Response (stable/progressive disease) 37 20
Not validated 5 3
Metachronous brain failure 58 32
Distant failure 89 48
Local failure 37 20
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prolonged TTP, DMFS and OS when compared to partial
remission.
Disease control becomes of prime importance in the
treated LD SCLC due to the early onset of metastases. A
number of studies have reported that the absolute majority
of patients with LD SCLC will develop a recurrence [1, 12,
16, 17]. Our analysis on the timing of treatment failure in
LD SCLC has demonstrated that in more than half of the
patients with distant relapse, failure occurred in the first
year from initial diagnosis [18]. Hence previous clinical tri-
als have addressed the question of the correlation between
treatment response, disease control and outcome after
CRT. A phase III trial published in 1997 by Jeremic et al.
firstly showed higher complete remission rates in patients
treated with early compared to late concurrent CRT corre-
lated with better long-term survival [9]. However, remis-
sion status itself was not analyzed as a prognostic factor.
Sixteen years later Sun et al. conducted a phase III study
Fig. 1 Overall survival in patient subgroups defined by remission status after CRT
Fig. 2 Distant metastasis-free survival in patient subgroups defined by remission status after CRT
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on the timing of TRT concurrent with chemotherapy with
complete remission rate as the primary endpoint. Early
and late TRT arms were found to be identical concerning
remission status and survival rates. The trial demonstrated
that complete responders independent of the timing of
TRT have significantly better prognosis compared to the
rest of the treated patients [8]. In contrast to the above
mentioned studies, the present analysis was conducted in
a heterogeneous patient cohort and aimed to compare
survival parameters between complete, partial and
non-responders. The importance of the achievement
of complete remission for the TTP, DMFS and OS was
emphasized. This fact may be considered in the plan-
ning and assessment of future multimodality trials for
LD SCLC.
The relevance of tumor shrinkage or downstaging
during the course of CRT was already investigated in
several smaller studies [19–21]. A correlation between
early metabolic (before start of TRT) and CT changes
of the tumor volume and survival in LD SCLC was
described by van Loon et al. [19]. Go et al. revealed that
downstaging during CRT can be considered as an inde-
pendent prognostic factor [20]. Also Fujii et al. reported
that the achievement of remission after the first cycle of
chemotherapy applied simultaneously with TRT was asso-
ciated with significantly better 2-year survival rate [21].
A major limitation of the present study is its retro-
spective nature. However, described treatment response
rates and survival correlated well with reported historical
data. Another important critical point is the heterogeneity
of the analyzed cohort but only 3 % of patients presented
with primary tumors <5 cm without lymph-node involve-
ment (UICC Stage I). Comprehensive retrospective acqui-
sition of the treatment toxicity was not possible and we
decided to analyze only medical charts of the patients who
completed definitive CRT without interruptions. More-
over an integration of the PET-CT (Positron emission
tomography–computed tomography) could not be exactly
evaluated, because fewer than 20 % percent of patients
received PET-CTs at initial staging. Nevertheless, present
results point out a clinical relevance of the complete re-
mission after definitive CRT and suggest that remission
status may be considered as an additional factor in the
planning and assessment of multimodality clinical trials
for LD SCLC.
Conclusion
In our retrospective analysis of heterogeneous LD SCLC
patient cohort, achievement of complete remission after
definitive CRT was associated with a relevant survival
Fig. 3 Time to progression in patient subgroups defined by remission status after CRT
Table 3 Survival parameters in the multivariate analysis after
adjustment for other prognostic factors
Survival Complete versus
partial remission
(HR and p value)
Complete remission
versus non-response
(HR and p value)
Median OS 1.267
(95CI: 0.899 – 1.787)
p = 0.177
2.135
(95CI: 1.392 – 3.275)
p = 0.001
Median DMFS 1.632
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advantage compared to the patients with stable/progres-
sive disease and especially partial responders.
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